Business Context and Reporting Period
This Form 6-K filing by Novo Nordisk A/S, dated March 23, 2026, reports on the company's ongoing share repurchase programme. Novo Nordisk is a leading global healthcare company headquartered in Denmark, employing approximately 68,800 people across 80 countries. The filing details transactions executed under a programme initiated on February 4, 2026, with a total authorization of up to DKK 15 billion over a 12-month period.
Key Financial Metrics
The filing focuses exclusively on capital allocation activities regarding share buybacks and does not report operational financial metrics such as revenue, profit, cash flow, or debt levels.
- Total Repurchase Authorization: Up to DKK 15 billion (12-month period starting February 4, 2026).
- Current Programme Tranche: Up to DKK 3.8 billion (February 4, 2026 to May 4, 2026).
- Total Shares Repurchased (since Feb 4, 2026): 7,847,992 B shares.
- Total Transaction Value: DKK 2,091,696,255.
- Average Purchase Price: DKK 266.53 per B share.
- Treasury Shares Held: 25,237,791 B shares (0.6% of total share capital).
Material Changes
Since the last announcement on March 16, 2026, the company executed five additional transactions between March 17 and March 20, 2026. These transactions involved the purchase of 1,270,000 B shares at an aggregate value of approximately DKK 308 million. The average purchase price for these specific recent transactions ranged from DKK 235.26 to DKK 250.48.
Guidance, Outlook, and Risks
Management expects to continue repurchasing B shares up to the total authorized amount of DKK 15 billion during the 12-month period beginning February 4, 2026. The filing notes that the programme is conducted in accordance with the EU Market Abuse Regulation (MAR) and Safe Harbour Rules. No specific operational risks, contingencies, or unusual items regarding the company's core business were disclosed in this specific filing.
Investor Verification Checklist
- Verify the remaining balance of the DKK 15 billion authorization after the DKK 2.09 billion spent to date.
- Confirm the current market price of Novo Nordisk B shares relative to the recent average buyback price of DKK 266.53.
- Review the full transaction history on novonordisk.com for granular daily execution data.
- Check subsequent filings for updates on the total treasury share count and percentage of share capital.